Literature DB >> 26346776

A Qualitative Review on the Pharmacokinetics of Antibiotics in Saliva: Implications on Clinical Pharmacokinetic Monitoring in Humans.

Tony K L Kiang1, Mary H H Ensom2,3.   

Abstract

We conducted a systematic search to describe the current state of knowledge regarding the utility of saliva for clinical pharmacokinetic monitoring (CPM) of antibiotics. Although the majority of identified studies lacked sufficient pharmacokinetic data needed to assign an appropriate suitability classification, most aminoglycosides, fluoroquinolones, macrolides, penicillins/cephalosporins, and tetracyclines are likely not suitable for CPM in saliva. No clear pattern of correlation was observed between physiochemical properties that favor drug distribution into saliva and the likelihood of the antibiotic being classified as suitable for CPM in saliva (and vice versa). Insufficient data were available to determine if pathophysiological conditions affected salivary distribution of antibiotics. Additional confirmatory data are required for drugs (especially in patients) that are deemed likely suitable for CPM in saliva because only a few studies were available and many focused only on healthy subjects. All studies identified had relatively small sample sizes and exhibited large variability. Very few studies reported salivary collection parameters (e.g., salivary flow, pH) that could potentially have some impact on drug distribution into saliva. The available data are heavily weighted on healthy subjects, and insufficient data were available to determine if pathophysiology had effects on saliva drug distribution. Some studies also lacked assay sensitivity for detecting antibiotics in saliva. Overall, this review can be useful to clinicians who desire an overview on the suitability of saliva for conducting CPM of specific antibiotics, or for researchers who wish to fill the identified knowledge gaps to move the science of salivary CPM further.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26346776     DOI: 10.1007/s40262-015-0321-z

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  84 in total

1.  Rifampin. Levels in serum and saliva and effect on the meningococcal carrier state.

Authors:  L F Devine; D P Johnson; C R Hagerman; W E Pierce; S L Rhode; R O Peckinpaugh
Journal:  JAMA       Date:  1970-11-09       Impact factor: 56.272

2.  Comparative pharmacokinetics of dirithromycin and erythromycin in normal volunteers with special regard to accumulation in polymorphonuclear leukocytes and in saliva.

Authors:  H F Geerdes-Fenge; B Goetschi; M Rau; K Borner; P Koeppe; K Wettich; H Lode
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

3.  Concentration of 3 tetracyclines in plasma, gingival crevice fluid and saliva.

Authors:  D Sakellari; J M Goodson; A Kolokotronis; A Konstantinidis
Journal:  J Clin Periodontol       Date:  2000-01       Impact factor: 8.728

4.  Moxifloxacin distribution in the interstitial space of infected decubitus ulcer tissue of patients with spinal cord injury measured by in vivo microdialysis.

Authors:  Olaf Burkhardt; Hartmut Derendorf; Doris Jäger; Vipul Kumar; Rajanikanth Madabushi; Klaus Röhl; Jürgen Barth
Journal:  Scand J Infect Dis       Date:  2006

Review 5.  Review: The physiology of saliva and transfer of drugs into saliva.

Authors:  Johan K M Aps; Luc C Martens
Journal:  Forensic Sci Int       Date:  2005-06-10       Impact factor: 2.395

6.  Penetration of penicillin V to tonsillar surface fluid in healthy individuals and in patients with acute tonsillitis.

Authors:  A Stjernquist-Desatnik; P Samuelsson; M Walder
Journal:  J Laryngol Otol       Date:  1993-04       Impact factor: 1.469

7.  Pharmacokinetics of rifampin in infants and children: relevance to prophylaxis against Haemophilus influenzae type b disease.

Authors:  G H McCracken; C M Ginsburg; T C Zweighaft; J Clahsen
Journal:  Pediatrics       Date:  1980-07       Impact factor: 7.124

8.  Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.

Authors:  U Jaehde; F Sörgel; A Reiter; G Sigl; K G Naber; W Schunack
Journal:  Clin Pharmacol Ther       Date:  1995-11       Impact factor: 6.875

9.  Ofloxacin for prevention of bacterial infections in granulocytopenic patients.

Authors:  W Kern; E Kurrle; E Vanek
Journal:  Infection       Date:  1987 Nov-Dec       Impact factor: 3.553

10.  Therapeutic drug monitoring in interstitial fluid: a feasibility study using a comprehensive panel of drugs.

Authors:  Tony K L Kiang; Veronika Schmitt; Mary H H Ensom; Beverly Chua; Urs O Häfeli
Journal:  J Pharm Sci       Date:  2012-08-31       Impact factor: 3.534

View more
  7 in total

Review 1.  Accessing analytes in biofluids for peripheral biochemical monitoring.

Authors:  Jason Heikenfeld; Andrew Jajack; Benjamin Feldman; Steve W Granger; Supriya Gaitonde; Gavi Begtrup; Benjamin A Katchman
Journal:  Nat Biotechnol       Date:  2019-02-25       Impact factor: 54.908

2.  Membrane Filtration Is Suitable for Reliable Elimination of Mycobacterium tuberculosis from Saliva for Therapeutic Drug Monitoring.

Authors:  Simone H J van den Elsen; Tridia van der Laan; Onno W Akkerman; Adri G M van der Zanden; Jan-Willem C Alffenaar; Dick van Soolingen
Journal:  J Clin Microbiol       Date:  2017-08-09       Impact factor: 5.948

3.  Single-Arm Open-Label Clinical Trial of Two Grams of Aztreonam for the Treatment of Neisseria gonorrhoeae.

Authors:  Lindley A Barbee; Olusegun O Soge; Negusse Ocbamichael; Angela LeClair; Matthew R Golden
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

Review 4.  Key Components for Antibiotic Dose Optimization of Sepsis in Neonates and Infants.

Authors:  Tamara van Donge; Julia A Bielicki; John van den Anker; Marc Pfister
Journal:  Front Pediatr       Date:  2018-10-29       Impact factor: 3.418

Review 5.  Revolutionizing Therapeutic Drug Monitoring with the Use of Interstitial Fluid and Microneedles Technology.

Authors:  Tony K L Kiang; Sahan A Ranamukhaarachchi; Mary H H Ensom
Journal:  Pharmaceutics       Date:  2017-10-11       Impact factor: 6.321

6.  Membrane Transporters in Human Parotid Gland-Targeted Proteomics Approach.

Authors:  Joanna Lapczuk-Romanska; Diana Busch; Ewa Gieruszczak; Agnieszka Drozdzik; Katarzyna Piotrowska; Robert Kowalczyk; Stefan Oswald; Marek Drozdzik
Journal:  Int J Mol Sci       Date:  2019-09-28       Impact factor: 5.923

7.  Clinical Value of Emerging Bioanalytical Methods for Drug Measurements: A Scoping Review of Their Applicability for Medication Adherence and Therapeutic Drug Monitoring.

Authors:  Tanja R Zijp; Zamrotul Izzah; Daan J Touw; Job F M van Boven; Christoffer Åberg; C Tji Gan; Stephan J L Bakker
Journal:  Drugs       Date:  2021-11-01       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.